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During the past decades, resistance to antimicrobial 
agents has augmented remarkably throughout the 
world, causing major problems in chemotherapy of 
infectious diseases [1]. One of the most important  
resistances has been reported in methicillin-resistant 
Staphylococcus aureus (MRSA) that plays a crucial 
role in both community and hospital-acquired 
infections [2, 3]. Thus, extensive studies were 
conducted to overcome the obstacles related to the 
outbreak of antibiotic resistance in MRSA [1]. 
Antibiotic resistance in S. aureus has been mediated 
through various mechanisms, among which bacterial 
efflux pumps are considered to be important factors in 
resistance to different classes of antibiotics and other 
antimicrobial compounds. These pumps are 
Abstract  
Introduction:  
Antibiotic resistance has been a major health problem in recent years, which has led to 
a failure in the treatment of infectious diseases. Therefore, research to synthesize 
compounds that have antibiotic activity is very valuable. In the present study, four 
novel compounds (6a-d), derivatives of dichloroimidazole conjugated with triazole, 
were synthesized in order to obtain new bacterial efflux pump inhibitors (EPIs). 
Methods and Results:  
The derivatives were evaluated for their effects on the minimum inhibitory 
concentration (MIC) of ciprofloxacin against a methicillin and ciprofloxacin resistant 
Staphylococcus aureus (MCRSA) clinical isolate. Based on broth microdilution method 
assay, four derivatives at a minimum effective concentration (MEC) fortified the 
antibacterial efficacy of ciprofloxacin against MCRSA. MIC of ciprofloxacin decreased 
in the presence of novel compounds compared to ciprofloxacin alone between 2 to 64 
fold. These compounds were then evaluated for their potency as efflux pump inhibitors 
using a fluorometric assay. Results indicated an increase in accumulation of ethidium 
bromide (a known fluorescent substrate for the NorA pump) in the presence of each 
compound, like verapamil (a typical inhibitor of efflux pump), thus these compounds 
acted as inhibitors of the NorA pump. Moreover, the MTT assay confirmed that novel 
compounds did not demonstrate any cytotoxic effect against three cancer cell lines, HT-
29, MCF-7, Caco-2, and a normal mouse fibroblastic cell line, NIH-3T3. 
Conclusion: 
Collectively, our results propose these derivatives as therapeutic options in combination 
therapies to tackle antibiotic resistance. 
Keywords: Synthesis, Triazoles, Antibacterial activity, Cytotoxic activity, Inhibitors 
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transmembrane proteins that detoxify cells mediated by 
extruding of antibiotics and decrease their intracellular 
concentration [4, 5] which may produce multidrug 
resistance (MDR) in bacteria [3, 6]. Several cases of 
these pumps have been reported in S. aureus, causing 
drug resistance such as NorA, NorB, NorC, and MdeA 
that belongs to the Major Facilitator Superfamily 
(MFS) as well as MepA from the multidrug and toxic 
compound extrusion (MATE) family [7]. Accordingly, 
S. aureus is less sensitive to fluoroquinolone antibiotics 
(e.g., ciprofloxacin) due to the active exclusion from 
the cell by the NorA MDR efflux pump [4, 8]. 
The NorA efflux pump of S. aureus causes resistance 
to a broad series of dissimilar substrates [9, 10] 
including hydrophilic fluoroquinolones (ciprofloxacin, 
norfloxacin) [11], biocides (acriflavine, cetrimide, 
benzalkonium chloride) [10, 12], verapamil [13], 
reserpine, and dyes (ethidium bromide, rhodamine, 
acridines) [14]. 
Consequently, particular attention has been focused to 
surmount resistance mechanisms such as the use of the 
efflux pump inhibitors (EPIs) [15, 16].  Use of these 
compounds in combination therapy helps to enhance 
the efficacy of antibiotics and decrease their 
therapeutic doses [14, 17]. In this regard, numerous 
researches have started deriving various EPIs from 
natural products (such as phytochemicals) and produce 
synthetic compounds [18, 19]. It has been observed 
that some of these compounds have the ability to 
increase the effectiveness of antimicrobial agents in 
combination therapies [1, 20] and thereby reduce the 
effective therapeutic dose of antimicrobial drugs [17, 
21]. Recent studies have reported the 
dicholoroimidazole and 1,2,4-triazole derivatives with 
antimicrobial [22, 23] and MDR inhibitory effects [24, 
25]. In the present study, we synthesized four novel 
derivatives of dichloroimidazole conjugated with 
triazole and evaluated their effects on the minimum 
inhibitory concentration (MIC) of ciprofloxacin. 
Following in-vitro cytotoxicity study, efflux assay was 
performed to assess the aforementioned compounds as 
novel EPIs. 
 2. Materials and Methods 
2.1. General remarks 
Melting points were determined with a Reichert-hot 
stage microscope and are uncorrected. 1H NMR spectra 
were recorded on a 500 MHz Brucker spectrometer 
using CDCl3 or DMSO-d6 as a solvent. Chemical shifts 
(δ) are reported in ppm relative to TMS as an internal 
standard. Infra spectra were acquired on a Nicolet 
Magna 550-FT-spectrometer. Mass spectra were 
obtained with a Finnigan Mat TSQ-70 spectrometer. 
Elemental analysis was within ± 0.4% of the theoretical 
values for C, H, and N. All other chemicals for 
synthesis were obtained from Merck (Darmstadt, 
Germany). Dimethyl sulfoxide (DMSO; Merck) was 
used to prepare the stock solutions of derivatives. The 
final concentration of DMSO was less than 1-2% 
without any undesirable effect on cell viability. 
Ciprofloxacin and verapamil were purchased from 
Shahid Ghazi and Rouzdaro Co. (Tehran, Iran), 
respectively. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was obtained 
from Sigma (St. Louis, MO, USA). 
2.2. Synthesis 
2.2.1. (4,5-dichloroimidazole-1-yl) propionic acid 
methyl ester (3) 
To a solution of compound 1 [26], (0.1 mol, 13.7 g) in 
200 mL chloroform, 0.1 mol of methyl acrylate (8.6 g), 
and 5 mL triethylamine were added and refluxed for 16 
h.  
The solvent was removed under reduced-pressure. 
Purification was carried out by column 
chromatography on silica using a mixture of 
dichloromethane and hexane as mobile phase. The 
mixture was crystallized from ether :n-hexane (3:1 v/v) 
to give 20.4 g (92%) of compound 3.  
m. p. = 45-47 °C, 1H NMR (CDCl3) δ: 2.8 (t, J = 7.5 
Hz, 2H, CH2-CO), 3.70 (s, 3H, OCH3), 4.25 (t, J = 7.5 
Hz, 2H), 7.47 (s, 1H, H-imidazole). IR (KBr) Ѵ: 1738 
cm-1. Mass: m/z (%) 222 (61), 191 (20), 149 (38), 113 
(100), 86 (60). 
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2.2.2. (4,5-dichloroimidazole-1-yl) propionic acid 
hydrazide (4) 
A solution of 3 (0.03 mol) in methanol (20 mL) was 
stirred in a cold water bath and then, 1.5 mL of 
hydrazine 98% was added. The mixture was stirred for 
3 h, and the precipitate was collected and washed with 
a few mL of methanol and chloroform. The yield was 
80%.  m. p. = 65-67 °C 1H NMR (DMSO-d6) δ: 2.51 (t, 
J = 7.0 Hz, 2H), 4.19 (t, J = 7.0 Hz, 2H), 7.70 (s, 1H, 
H-imidazole), 9.11 (bs, 1H, NH). IR (KBr) °C: 3328, 
3180, 3099, 1678 cm-1. Mass: m/z (%) 222 (30), 187 
(45), 163 (75), 150 (100), 85 (43), 67 (72). 
2.2.3. General Procedure for N1-aryl-N2-(4,5-
dichloroimidazole-1-yl) propionic acid) carboxamide 
thiourea (5a-d) 
To a solution of 4 (0.01 mol) in 2 mL of ethanol, aryl 
isothiocyanates (0.01 mol), and 5 mL of NaOH 
solution (2N) were added. The mixture was stirred for 
3 h at room temperature. The pH was adjusted to 2 by 
adding concentrated hydrogen chloride solution. The 
mixture was stored at 4 °C for 24 h. Related 
thiosemicarbazides were removed by filtration and 
directly used for next step. 
2.2.4. General procedures For 4-aryl-5-(4,5-
dichloroimidazole-1-yl-ethyl)-2,4-dihydro-[1,2,4]-
triazole-3-thiones (6a-d) 
To 0.01 moles of compound 5 10 mL of saturated 
sodium carbonate solution was added and refluxed for 
5 h. After cooling, hydrogen chloride was added and, 
the precipitate was filtered. Crystallization from 
methanol and water gave compounds 6. 
2.2.4.1. 4-(Phenyl)-5-(4,5-dichloroimidazole-1-yl-
ethyl)-2,4-dihydro-[1,2,4]-triazole-3-thione (6a) 
% yield = 78,  m. p. = 240-241 °C, 1H NMR (DMSO- 
d6) δ: 2.70 (t, J = 6.8 Hz, 2H, CH2), 4.23 (t, J = 6.8 Hz, 
2H, CH2), 7.16 (m, 3H), 7.36 (m, 2H), 7.75 (s, 1H, H-
imidazole), 9.5 (bs, 1H, NH), IR (KBr) Ѵ: 3656, 3250, 
1690 cm-1, Mass: m/z (%) 264 (10), 227 (18), 186 (25), 
149 (20), 135 (100), 98 (20), 77 (55), Anal. Calcd. for 
C13H11Cl2N5S: C, 45.89; H, 3.25; N, 20.58. Found: C, 
45.65; H, 3.21, N, 20.50. 
2.2.4.2. 4-(4-Nitrophenyl)-5-(4,5-dichloroimidazole-
1-yl-ethyl)-2,4-dihydro-[1,2,4]-triazole-3-thione (6b) 
% yield = 90,  m. p. = 120-123 °C, 1H NMR (DMSO-
d6) δ: 2.73 (t, J = 6.4 Hz , 3H, CH2), 4.25 (t, J = 6.4 Hz 
, 2H, CH2), 7.75 (s, 1H, H-imidazole), 7.86 (d, J = 7.8 
Hz , 2H), 8.20 (d, J = 7.8 Hz , 2H), 10.05 (bs, 1H, NH). 
IR (KBr) Ѵ: 3322, 1664, 1530, 1348 cm-1, Mass: m/z 
(%) 265 (5), 222 (10), 181 (65), 135 (100), 91 (79), 66 
(85), Anal. Calcd. for C13H10Cl2N6O2S: C, 40.53; H, 
2.62; N, 21.82. Found: C, 40.66; H, 2.47, N, 21.75. 
2.2.4.3. 4-(4-Chlorophenyl)-5-(4,5-dichloroimidazole-
1-yl-ethyl)-2,4-dihydro-[1,2,4]-triazole-3-thione (6c) 
% yield = 70, m. p. = 175-177 °C, 1H NMR (DMSO- 
d6) δ: 2.73 (t, J = 7.1 Hz, 2H, CH2), 4.30 (t, J = 7.1 Hz, 
2H, CH2), 7. 5 (m, 4H), 7.78 (s, 1H, H-imidazole), 9.6 
(bs, 1H, NH), IR (KBr) Ѵ: 3367, 1680 cm-1, Mass: m/z 
(%) 264 (10), 246 (15), 225 (10), 187 (15), 169 (100), 
112 (38), 76 (39), Anal. Calcd. for C13H10Cl3N5S: C, 





% yield = 90  m. p. = 161-163 °C, 1H NMR (DMSO- 
d6) δ: 2.96 (t, J = 7.1 Hz , 2H, CH2), 3.75 (s, 3H, 
OCH3), 4.22 (t, J = 7.0 Hz , 2H, CH2), 6.90 (d, J = 7.5 
Hz , 2H), 7.22 (d, J = 7.5 Hz , 2H), 7.75 (s, 1H, H-
imidazole), 9.6 (bs, 1H, NH), IR (KBr) Ѵ: 3322, 
16646, 1530, 1348 cm-1, Mass: m/z (%) 370 (M+, 2), 
222 (5), 186 (20), 186 (20), 165 (95), 151 (58), 124 
(100), Anal. Calcd. for C14H13Cl2N5OS: C, 45.41; H, 
3.54; N, 18.92. Found: C, 44.35, H, 3.54, N, 18.92. 
2.3. Biology 
2.3.1. Bacterial strain and media 
Ciprofloxacin and methicillin-resistant clinical isolate 
of S. aureus was obtained from the Imam Khomeini 
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Hospital, Karaj. The resistance of MRSA strain was 
confirmed by the Kirby-Bauer disk-diffusion assay. 
The following antibiotic disks were consumed: 
methicillin (30 µg/ mL), ciprofloxacin (5 µg/ mL), and 
oxacillin (1 µg/ mL) (Pad Tan Teb, Tehran, Iran). For 
determination of MICs and ethidium bromide (EtBr) 
accumulation experiments, the cultures were grown in 
Muller-Hinton broth (MHB; Merck) at 37 °C. 
2.3.2. Cell culture 
The human colon adenocarcinoma (HT-29), human 
breast adenocarcinoma (MCF-7), colorectal 
adenocarcinoma (Caco-2), and a mouse embryonic 
fibroblast cell line (NIH-3T3) [27, 28] were obtained 
from National Cell Bank, Pasteur Institute (Tehran, 
Iran). The  cells were cultured in RPMI-1640 medium 
(Biosera, East Sussex, UK), containing 10% heat-
inactivated Fetal Bovine Serum (FBS; Gibco, CA, 
USA), 1% penicillin-streptomycin (Biosera) and were 
kept in humidified 5% CO2 incubator at 37 °C. 
However, Caco-2 cells were maintained in 50% RPMI-
1640, 35% DMEM/F12 (Biosera), 15% FBS, and 1% 
penicillin-streptomycin.  
2.3.3. Determination of MICs 
In this study, MICs of ciprofloxacin and derivatives 
against MCRSA were determined by the broth micro-
dilution method based on the criteria of Clinical and 
Laboratory Standards Institute (CLSI) [3]. Briefly, 
suspension equal to a 0.5 McFarland standards was 
prepared (106 CFU/ mL S. aureus were inoculated into 
MHB) from the culture which was incubated for 18 h 
at 37 °C. Then, the suspension was diluted to give the 
final concentration of 5 × 105 CFU/ mL and was added 
to a serial dilution of the ciprofloxacin (0.25-500 µg/ 
mL) and 6a-d (1.22-250 µg/ mL) in 96-well plates. 
MIC value was determined as the lowest concentration 
with no visible growth (no obvious turbidity). 
Afterwards, the effect of compounds 6a-d on the MIC 
of ciprofloxacin was evaluated. For this purpose, MIC 
of ciprofloxacin in combination with 1/2 MIC of 6a-d 
was specified by the broth micro-dilution method 
against MCRSA. 
2.3.4. Effect of compounds on accumulation of EtBr 
In order to assess the effect of compounds as efflux 
pump inhibitors, EtBr accumulation measurement was 
performed by fluorimetry. Since verapamil is a known 
efflux inhibitor, it was used as a positive control at a 
concentration of 100 µg/ mL [2, 29]. Therefore, the 
level of EtBr accumulation in MCRSA in the presence 
and absence of inhibitors was evaluated according to 
previous reports [4, 15, 30]. Briefly, bacterial 
suspensions with an optical density of 0.2 at 550 nm 
were ready in uptake buffer (110 mM NaCl, 7 mM 
KCl, 50 mM NH4Cl, 0.4 mM Na2HPO4, 52 mM Tris 
base and 0.2% glucose, adjusted to pH 7.5 with HCl). 
Then, the suspensions were exposed to EtBr (Merck) at 
a concentration of 2 µg/ mL with EPIs at MEC 
(minimal concentration of EPIs that produced the 
maximal reduction in MIC of ciprofloxacin, for 
compound 6a and 6b at 78.125 µg/ mL, for compound 
6c at 19.53 µg/ mL and for compound 6d at 156.25 µg/ 
mL). Upon EtBr penetration into the cells, the increase 
in fluorescence was measured spectrophotometrically 
for fourty five minutes at intervals of five minutes 
while 530 nm and 600 nm were adjusted for excitation 
and emission wavelengths, respectively.  
2.3.5. Cell viability assay 
Since the antibacterial agents should demonstrate no or 
confined harmful side effects against the host cell, the 
effects of new derivatives on four different cell lines 
(HT-29, MCF-7, Caco-2, and NIH-3T3) were 
evaluated by conventional MTT assay [8, 28]. The 
cells (8000-1000 cells/well) were seeded into 96-well 
plates and incubated at 37 °C for 48 h. Subsequently, 
the cells were treated with different concentrations of 
each compound (62.5-1000 µg/ mL).  Following 48 h 
incubation, the medium was discarded and 20 µL of 
MTT solution (5 mg/ mL in PBS) was added to each 
well and incubated for additional 4 h. Then, 100 µL of 
DMSO was used to dissolve formazan crystals. 
Eventually, the absorbance was determined at 570 nm 
with a reference wavelength of 690 nm by a plate 
reader (Anthos 2020, Biochrom, Cambridge, UK). The 
cytotoxicity is expressed as the concentration of 
compounds which inhibits the growth of 50% of cells 
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compared with vehicle-treated cells. The results were 
presented as the mean ± standard deviations for at least 




The previously reported reaction of aryl-hydrazide and 
the appropriate isothiocyanate was extended for the 
preparation of compounds 6 [31]. The synthetic 
reactions used for the preparation of 4-aryl-5-(4,5-
dichloroimidazole-1-yl-ethyl)-2, 4-dihydro-1, 2, 4-
triazole-3-thiones are outlined in scheme 1. Starting 
from (4,5-dichloroimidazole-1-yl) propionic acid 
hydrazide 4, intermediate 5 were prepared. The 
compounds 5 were cyclized in saturated sodium 
carbonate solution to give the final compounds (6a-d) 
with good yield. Hydrized 4 was synthesized from 
compound 3 through the reaction with hydrazine.    
(4,5-Dichloroimidazole-1-yl) propionic acid methyl 
ester 3 was prepared from 4,5-dichloroimidazole 1 and 
methyl acrylate 2 through a Michel addition reaction.  
 
Scheme 1. Synthesis pathway for preparation of 1,2,4-
triazole-3-thions 
3.2. Susceptibility study of MRSA strain and MIC 
determination 
Initially, the MIC value of ciprofloxacin against 
MCRSA was determined. We next defined the MIC of 
newly synthesized compounds to obtain concentration 
at which does not have any bacterial toxicity. Thus, 
their effectiveness was investigated only as EPIs. As 
summarized in Table 1, the MIC value of ciprofloxacin 
was 62.5 µg/mL while the MIC values of 156.5, 312.5, 
1250, and 312.5 µg/ mL were determined for 6a-d 
derivatives, respectively. Furthermore, MIC of 
ciprofloxacin (with a sub-inhibitory concentration) in 
combination with 1/2 MIC of compounds was 
evaluated using broth micro-dilution method against 
MCRSA. It was uncovered that MIC of ciprofloxacin 
decreased in the presence of novel compounds relative 
to ciprofloxacin alone with 2 to 64 fold decrease.  
Table 1. Minimum inhibitory concentration (MIC) values of ciprofloxacin alone and in combination with 
compounds 6a-d. 
Reduction (n-
fold) in MIC of 
ciprofloxacin 
MIC of ciprofloxacin (µg/ 
mL)  
MEC of EPI 
(µg/ mL) 
MIC of EPI 
(µg/ mL) 
EPI 
 Without EPI           With EPI 
  2 31.25 62.5 78.125 156.25 6a 
4 15.6 62.5 78.125 312.5 6b 
64 0.97 62.5 19.53 1250 6c 
2 31.25 62.5 156.25 312.5 6d 
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3.3. Effect of EPIs on accumulation of EtBr 
Since the newly synthesized compounds decreased the 
MIC of ciprofloxacin, we examined their efficacy as 
inhibitors of NorA by evaluating their effects on 
accumulation of EtBr (a known fluorescent substrate 
for the NorA pump). The EtBr emits fluorescence upon 
binding to nucleic acids within the cells. An EPI 
compound leads to a significant increase due to the 
accumulation of EtBr in the bacteria [4, 32]. Figure 1 
demonstrates the effect of the compounds on the 
accumulation of EtBr in comparison with the 
 
Figure 1. Accumulation of EtBr in MRSA in presence of 
compound 6a (■), compound 6b (□), compound 6c (▼), 
compound 6d (∆), and verapamil (○) as a positive control, 
and without EPIs (●) as a negative control. Results were 
expressed as mean ± standard deviations for two 
independent experiments. 
untreated control group as a negative control and 
verapamil as a positive control. 
As shown in Figure 1, a remarkable increase in 
fluorescence was observed in the presence of each 
compound, though it was less than verapamil. This 
increase arises from the reduction of EtBr exit from the 
bacteria attributed to inhibition of efflux pump. While 
in control cells without EPIs, fluorescence was reduced 
due to efflux of EtBr. 
3.4. Effect of compounds 6a-d on in-vitro 
cytotoxicity 
The cytotoxicity was evaluated on four different cell 
lines (HT-29, MCF-7, Caco-2, and NIH-3T3) by 
treating the cells with different concentrations of the 
compounds 6a-d using an MTT colorimetric assay 
(25). The results from three independent experiments 
were reported in Table 2. It was observed that most of 
the tested compounds at MEC concentration did not 
demonstrate cytotoxic activity against cancer cell lines. 
Only, exposure to increasing concentrations of 
compound 6b abolished cell growth of MCF-7 with an 
IC50 value of 115 ± 7.07 μg/ mL. In the case of normal 


















Table 2. Structure and cytotoxicity of compounds 6a-d 
 
 
Cytotoxicity (IC50, µg/ mL)*  
NIH-3T3 Caco-2 MCF-7 HT-29 R Compounds 
338.5 ± 4.94 553 ± 31.8 239.5 ± 3.5 383.3 ± 4.9 H 6a 
95 ± 1.4 >1000 115 ± 7.07 >1000 NO2 6b 
264 ± 5.65 245 ± 7.07 213.33 ± 11 552 ± 2.82 Cl 6c 
550 ± 30 636 ± 9.29 >1000 >1000 OCH3 6d 
* Values are the mean ± SD. All experiments were performed at least three times. 
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4. Discussion and Conclusion 
One of the most important mechanisms of resistance 
elucidated in S. aureus is the efflux pumps, causing 
decrease in the intracellular concentration of antibiotics 
[2]. This phenomenon is considered as one of the main 
resistance factors to fluoroquinolones and other 
compounds in clinical isolates of S. aureus [15]. As a 
result, extensive researches have been conducted for 
synthesizing efflux pump inhibitors to prevent 
infections caused by S. aureus and emergence of new 
MDR strains [3]. In this regard, Chan et al. found that 
baicalein could significantly reduce the ciprofloxacin 
resistance in MRSA strains attributed to the NorA 
efflux pump inhibition [33]. Previous study clarified 
new analogues of piperine, an active component of 
Piper nigrum, as NorA pump inhibitors in S. aureus 
[4]. Moreover, Pourmand and colleagues demonstrated 
the hexahydroquinoline derivatives with the ability to 
decrease the MIC of ciprofloxacin and enhance the 
antibacterial effect of ciprofloxacin against MRSA [3].  
There are some evidences that dicholoroimidazole and 
1, 2, 4-triazole derivatives have demonstrated anti-
microbial effects [22, 23]. Besides, MDR inhibition 
properties in triazole derivative were observed [24, 25]. 
In this study, we synthesized four novel derivatives of 
dichloroimidazole conjugated with triazole and 
investigated their antibacterial potency as EPIs. It 
should be noted that the sub-inhibitory concentration of 
ciprofloxacin and compounds 6a-d was chosen to 
ensure that their effect was produced collectively not 
individually. Thus, the results obtained in these 
conditions could be due to the compounds intervention 
in antibiotic resistance. Our results indicated that these 
new compounds promoted the antibacterial activity of 
ciprofloxacin. Compounds 6a and d caused a 2-fold 
decrease in MIC of ciprofloxacin whereas compound 
6b demonstrated a 4-fold decrease. Additionally, 
compound 6c efficiently attenuated the MIC of 
ciprofloxacin with a 64-fold reduction. Although all 
compounds reduced the MIC of ciprofloxacin, this 
effect was noticeable for compound 6c. Since these 
compounds are different only in one substitution, it 
seems that significant effect of compound 6c arises 
from the existence of Cl substitution. 
Regarding the previous studies corroborating the 
presence of efflux pump in S. aureus [12], compounds 
6a-d can alter the MIC of ciprofloxacin in MRSA by 
inhibition of this pump. On the other hand, it is 
recognized that MDR pumps of many Gram-positive 
bacteria such as NorA or NorB are transporter of EtBr. 
Thus, the effect of these new compounds on the efflux 
pump was evaluated by EtBr (resistance to EtBr is only 
mediated through the efflux pumps) [15, 34]. Our 
findings indicated that newly synthesized compounds 
led to the accumulation of EtBr compared with control 
cells without EPI in a similar way that verapamil does, 
implying their capability as  the NorA suppressors. 
Similarly, Fontaine et al. investigated the effects of a 
series of boronic derivatives as efflux pump inhibitors 
against susceptible and resistant S. aureus strains. The 
results demonstrated that these compounds increased 
the activity of ciprofloxacin, norfloxacin, and 
reinforced EtBr accumulation [9]. In addition, it has 
been revealed that exposure to galbanic acid inhibits 
the efflux of EtBr in clinical isolates of S. aureus [15]. 
Since these candidates for use in combination therapy 
should not have cytotoxic effects, the cytotoxicity of 
them was evaluated against a panel of cell lines in the 
presence of compounds 6a-d. Compounds 6a and d 
inhibited less than 25% of the cell growth in four cell 
lines at MEC. Intriguingly, 6c (the most promising 
compounds to inhibit the NorA efflux pump and reduce 
the MIC of ciprofloxacin) had the lowest level of cell 
growth inhibition and cytotoxicity (approximately less 
than 10% at MEC for all cell lines). Only compound 6b 
demonstrated a moderate level of toxicity at MEC on 
MCF-7 and NIH-3T3 cell lines (35% and 45%, 
respectively). 
In summary, four novel derivatives of 
dichloroimidazole were synthesized which have 
exerted significant potential for reducing the resistant 
of S. aureus strains and emerged as the efflux pump 
inhibitors. These new compounds particularly 
compound 6c, the most effective compound with the 
lowest level of toxicity, can be used as putative 
inhibitors of antibiotic resistance in combination 
therapies against S. aureus. Considering the outbreak 
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of antibiotic resistance in MRSA strain, our findings 
have proposed compound 6c as a plausible NorA 
inhibitor to overcome this obstacle. Moreover, further 
studies are needed to evaluate the expression of efflux 
pump gene in the presence of these compounds in 
MCRSA using molecular techniques. 
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